Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.59 |
| ▸ | SKP1 | P63208 | 1/20 | 0.59 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.59 |
| ▸ | ACACB | O00763 | 10/20 | 0.52 |
| ▸ | ACACA | Q13085 | 10/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066437 | 0.83 | CKS1B (0.54) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL6697501 | 0.82 | CKS1B (0.61) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL23174251 | 0.82 | CKS1B (0.61) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL6066402 | 0.82 | CKS1B (0.61) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL12916519 | 0.82 | GPR119 (0.57) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL6066417 | 0.81 | GPR119 (0.61) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL6066394 | 0.80 | CKS1B (0.54) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL13556492 | 0.80 | CKS1B (0.56) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL13472398 | 0.80 | CKS1B (0.58) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL7239787 | 0.79 | SYK (0.56) | CKS1BSKP1SKP2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGA1, ITGB1, ITGA5 | CKS1B 934/4885SKP1 1784/4885SKP2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.